SEC Form 4 · accession 0001737287-26-000019
Allogene Therapeutics, Inc. · ALLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Mayo
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 4:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001737287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $2.00 | Jun 18, 2026 | A | 144,400 | A | — | Jun 18, 2036 | Common Stock | 144,400 | 144,400 | D |
Explanation of responses
- F1Vesting in 12 equal monthly installments.